UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016783
Receipt number R000019471
Scientific Title Study of treatment starategy for patients with castration resistsnt prostate cancer using new hormonal agents before chemotherapy
Date of disclosure of the study information 2015/04/01
Last modified on 2018/09/12 12:17:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of treatment starategy for patients with castration resistsnt prostate cancer using new hormonal agents before chemotherapy

Acronym

Starategy for pre-chemo CRPC

Scientific Title

Study of treatment starategy for patients with castration resistsnt prostate cancer using new hormonal agents before chemotherapy

Scientific Title:Acronym

Starategy for pre-chemo CRPC

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To know impact of new hormonal agents (Enzalutamide and abiraterone) in patients with castration resistant prostate cancer before chemotherapy

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

PSA resopnse

Key secondary outcomes

QOL
Duration before chemotherapy
Skeletal related event
Survival


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male

Key inclusion criteria

1. Pathologicalyconfirmation of prostate cancer
2. Castration resistant prostate cancer
3. Next treatment: Enzalutamide or abiraterone
4. No chemotherapy
5. No steroids
6. Performance status 0-1

Key exclusion criteria

1. Other malignancies
2. Prior chemotherapy (excluding estramuscin)
3. Steroids
4. Severe visceral dysfunction
5. Other clinical trial
6. Prior enzalutamide or abiraterone

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mitsuzuka Koji

Organization

Tohoku University School of Medicine

Division name

Urology

Zip code


Address

1-1 Seiryo-machi,Aoba-ku, Sendai, Miyagi 980-8574, Japan

TEL

022-717-7278

Email

yarai@uro.med.tohoku.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mitsuzuka Koji

Organization

Tohoku University School of Medicine

Division name

Urology

Zip code


Address

1-1 Seiryo-machi,Aoba-ku, Sendai, Miyagi 980-8574, Japan

TEL

022-717-7278

Homepage URL


Email

mitsuzuka@uro.med.tohoku.ac.jp


Sponsor or person

Institute

Department of urology, Tohoku University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Astellas

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Clinical ressearch, Innovation and Education Center, Tohoku University Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

弘前大学(青森県)、秋田大学(秋田県)、宮城県立がんセンター(宮城県)、むつ総合病院(青森県)、青森県立中央病院(青森県)、青森労災病院(青森県)、八戸市民病院(青森県)、秋田赤十字病院(秋田県)、市立秋田総合病院(秋田県)、大館市立病院(秋田県)、岩手県立磐井病院(岩手県)、栗原中央病院(宮城県)、気仙沼市立病院(宮城県)、大崎市民病院(宮城県)、仙台医療センター(宮城県)、宮城県立がんセンター(宮城県)、仙台市立病院(宮城県)、柳生クリニック(宮城県)、東北公済病院(宮城県)、泉中央病院(宮城県)、仙塩利府病院(宮城県)、山形県立中央病院(宮城県)、白河厚生総合病院(福島県)、総合磐城共立病院(福島県)


Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2015 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 04 Month 01 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 09 Month 30 Day

Date trial data considered complete

2020 Year 09 Month 30 Day

Date analysis concluded

2021 Year 03 Month 31 Day


Other

Other related information

Prospective observation study
Efficiency of each drugs
Setquential effiiency among the drugs


Management information

Registered date

2015 Year 03 Month 11 Day

Last modified on

2018 Year 09 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019471


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name